Robertet SA (EPA:RBT)
France
· Delayed Price · Currency is EUR | Market Cap | 1.67B |
| Revenue (ttm) | 843.95M |
| Net Income (ttm) | 103.43M |
| Shares Out | 2.10M |
| EPS (ttm) | 47.29 |
| PE Ratio | 16.98 |
| Forward PE | 17.49 |
| Dividend | 12.00 (1.49%) |
| Ex-Dividend Date | Jun 29, 2026 |
| Volume | 5,984 |
| Average Volume | 1,904 |
| Open | 806.00 |
| Previous Close | 803.00 |
| Day's Range | 800.00 - 815.00 |
| 52-Week Range | 770.00 - 922.00 |
| Beta | 0.36 |
| RSI | 47.30 |
| Earnings Date | Apr 9, 2026 |
About Robertet
Robertet SA produces and sells perfumes, aromas, and natural products. The company operates in four segments: Raw materials, Fragrances, Flavors, and Active Ingredients. It also produces organic essential oils and active ingredients. The company operates in North America, Latin America, Europe, Africa, and the Middle East. Robertet SA was founded in 1850 and is headquartered in Grasse, France. [Read more]
Financial Performance
In 2025, Robertet's revenue was 843.95 million, an increase of 4.50% compared to the previous year's 807.63 million. Earnings were 103.43 million, an increase of 14.83%.
Financial StatementsNews
Robertet Earnings Call Transcript: H2 2025
Strong organic growth and margin expansion in 2025, with EBITDA margin up to 20.6% and net income rising 14.8%. Facing headwinds from FX, raw material, and transport costs, but maintaining disciplined investment and M&A strategy. Guidance for 2026 is cautious, targeting 5% revenue growth.
ROBERTET INVESTS IN AETHERA BIOTECH, A EUROPEAN PIONEER IN ACTIVE COSMETIC INGREDIENTS
ROBERTET INVESTS IN AETHERA BIOTECH, A EUROPEAN PIONEER IN ACTIVE COSMETIC INGREDIENTS Entering plant-based biotechnologies to advance Robertet's “Augmented Naturality” strategy Strengthening Robertet...
Robertet Earnings Call Transcript: H1 2025
Solid H1 2025 results with 9.2% organic growth, margin improvements, and strong performance in raw materials and flavors. U.S. tariffs and currency volatility pose headwinds for H2, but price increases and ongoing M&A are expected to support long-term growth.
Robertet Earnings Call Transcript: H2 2024
Double-digit sales and margin growth in 2024 were driven by all divisions and regions, with strong cash flow and reduced leverage. 2025 is expected to be a year of consolidation amid regulatory, tariff, and raw material cost risks, with continued focus on natural ingredients and global expansion.
Robertet Earnings Call Transcript: H1 2024
Strong H1 2024 results with 10.1% sales growth and 21.4% EBITDA margin, driven by restocking, favorable raw material costs, and successful integration of Sonarome. Full-year organic growth is targeted at 7%, with margin improvement expected despite H2 cost pressures.